What Fueled The Previous Growth In The Joint Pain Injections Market?
The joint pain injections market has seen considerable growth due to a variety of factors.
• Over the past few years, there has been significant growth in the joint pain injections market size. The market is expected to escalate from $5.6 billion in 2024 to $6.17 billion in 2025, marking a compound annual growth rate (CAGR) of 10.1%.
The surge in growth during the historical period can be credited to factors such as a rise in the aging population, an increase in arthritis cases, worldwide health initiatives, the digitalization of healthcare, and a climbing awareness concerning the management of chronic pain.
What Is The Expected Growth In The Joint Pain Injections Market Size?
The joint pain injections market is expected to maintain its strong growth trajectory in upcoming years.
• The market for joint pain injections is predicted to experience a swift expansion in the coming years, reaching $9.81 billion in 2029 with a compound annual growth rate (CAGR) of 12.3%.
This anticipated growth can be linked to the broadening of telehealth services, personalized pain management strategies, increased patient education and empowerment, sound healthcare practices, and nutritional support. Some key trends predicted for the forecast period consist of regenerative medicine, personalized pain management, innovative injection materials, rehabilitation technologies and injections improved by artificial intelligence (AI).
What Main Forces Are Fueling Expansion In The Joint Pain Injections Market?
The increase in the incidence of arthritis and musculoskeletal conditions is set to spur the expansion of the joint pain injections market. Musculoskeletal conditions hold the record for being the most prevalent cause of global disability, with lower back pain standing as the principal cause of disability in 160 countries. Administration of injections for alleviating pain and inflammation is a typical practice among patients. For instance, the Australian Institute of Health and Welfare, a governmental agency based in Australia, reported in June 2023 that rheumatoid arthritis was accountable for 2.0% of the total disease load and 16% of the overall load of disease tied to musculoskeletal conditions. In 2022, it was to blame for 1,322 fatalities, or 5.1 deaths for every 100,000 individuals, making up 0.7% of all deaths. Consequently, the burgeoning incidence of arthritis and musculoskeletal disorders propels the joint pain injections market.
What Are The Primary Segments In The Global Joint Pain Injections Market?
The joint pain injections market covered in this report is segmented –
1) By Type Of Injection: Steroid Joint Injection, Hyaluronic Acid Injections, Platelet-Rich Plasma (PRP) Injections, Placental Tissue Matrix (PTM) Injections, Other Type Of Injections
2) By Joint Type: Hip Joint, Knee And Ankle, Shoulder And Elbow, Facet Joints Of The Spine, Other Joint Types
3) By Distribution channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Steroid Joint Injection: Corticosteroid Injections, Combination Steroid Injections
2) By Hyaluronic Acid Injections: Single-Dose Hyaluronic Acid Injections, Multi-Dose Hyaluronic Acid Injections
3) By Platelet-Rich Plasma (PRP) Injections: Autologous PRP Injections, Allogeneic PRP Injections
4) By Placental Tissue Matrix (PTM) Injections: Amniotic Fluid Injections, Placental Derived Cell Injections
5) By Other Types of Injections: Bone Marrow Aspirate Concentrate (BMAC) Injections, Stem Cell Injections, Genetically Engineered Cell Injections
Pre-Book The Joint Pain Injections Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Key Trends Are Driving Changes In The Joint Pain Injections Market?
Leading businesses in the joint pain injection sector are concentrating on creating innovations such as single-injection formulations, which prioritizes patient convenience. A single-injection formulation is a specialized drug delivery approach that administers a precise medication dose in one injection, ensuring lasting therapeutic benefits over an extended period without multiple dose requirements. For example, LG Chem Ltd., a chemical firm based in South Korea, introduced Synovian, a novel treatment for knee osteoarthritis in China, in July 2024. This product is the first in the nation to offer a convenient single-injection formulation. It targets a substantial market predicted to be around KRW 200 billion (around USD 150 million). This innovative product developed with proprietary technology reflects a focus on meeting patient needs, emphasizing effective relief with reduced administration inconveniences.
Who Are the Key Players in the Joint Pain Injections Market?
Major companies operating in the joint pain injections market include:
• Seikagaku Corporation
• Flexion Therapeutics Inc.
• Zimmer Biomet Holdings Inc.
• Sanofi S.A.
• Anika Therapeutics Inc.
• Abbvie Inc.
• Bioventus Inc.
• Eli Lilly and Company
• Ferring Pharmaceuticals Inc.
• Pfizer Inc.
• Teva Pharmaceutical Industries Limited
• Johnson & Johnson Services Ltd.
• Merck & Co. Inc.
• GlaxoSmithKline plc
• Novartis AG
• AstraZeneca plc
• Roche Holding AG
• Bristol-Myers Squibb Company
• Boehringer Ingelheim International GmbH
• Takeda Pharmaceutical Company Limited
• Bayer AG
• Astellas Pharma Inc.
• Daiichi Sankyo Company Limited
• Eisai Co. Ltd.
• Ipsen SA
• Mallinckrodt Pharmaceuticals Ltd.
• Mylan N.V.
• Sun Pharmaceutical Industries Ltd.
• Wockhardt Ltd.
• Zydus Lifesciences Limited
What Is The Most Dominant Region In The Joint Pain Injections Market?
North America was the largest region in the joint pain injections market in 2024. The regions covered in the joint pain injections market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
